Titre : Effecteurs de type activateur de transcription

Effecteurs de type activateur de transcription : Questions médicales fréquentes

Termes MeSH sélectionnés :

Imagination
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Effecteurs de type activateur de transcription : Questions médicales les plus fréquentes", "headline": "Effecteurs de type activateur de transcription : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Effecteurs de type activateur de transcription : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-20", "dateModified": "2025-04-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Effecteurs de type activateur de transcription" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Facteurs de virulence", "url": "https://questionsmedicales.fr/mesh/D037521", "about": { "@type": "MedicalCondition", "name": "Facteurs de virulence", "code": { "@type": "MedicalCode", "code": "D037521", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.896" } } }, "about": { "@type": "MedicalCondition", "name": "Effecteurs de type activateur de transcription", "alternateName": "Transcription Activator-Like Effectors", "code": { "@type": "MedicalCode", "code": "D000071336", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Doron Teper", "url": "https://questionsmedicales.fr/author/Doron%20Teper", "affiliation": { "@type": "Organization", "name": "Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, 700 Experiment Station Road, Lake Alfred, FL 33850, U.S.A." } }, { "@type": "Person", "name": "Nian Wang", "url": "https://questionsmedicales.fr/author/Nian%20Wang", "affiliation": { "@type": "Organization", "name": "Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, 700 Experiment Station Road, Lake Alfred, FL 33850, U.S.A." } }, { "@type": "Person", "name": "Josh Tycko", "url": "https://questionsmedicales.fr/author/Josh%20Tycko", "affiliation": { "@type": "Organization", "name": "Department of Genetics, Stanford University, Stanford, CA 94305, USA." } }, { "@type": "Person", "name": "Michael C Bassik", "url": "https://questionsmedicales.fr/author/Michael%20C%20Bassik", "affiliation": { "@type": "Organization", "name": "Department of Genetics, Stanford University, Stanford, CA 94305, USA. Electronic address: bassik@stanford.edu." } }, { "@type": "Person", "name": "Lacramioara Bintu", "url": "https://questionsmedicales.fr/author/Lacramioara%20Bintu", "affiliation": { "@type": "Organization", "name": "Department of Bioengineering, Stanford University, Stanford, CA 94305, USA. Electronic address: lbintu@stanford.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A 68-Year-Old Woman Presenting with Recurrent Abdominal Pain and a Diagnosis of a Presacral Retroperitoneal Benign Schwannoma that Mimicked an Ovarian Tumor on Pelvic Magnetic Resonance Imagining.", "datePublished": "2022-07-20", "url": "https://questionsmedicales.fr/article/35854634", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.12659/AJCR.935985" } }, { "@type": "ScholarlyArticle", "name": "Acceptability and Utility of a Digital Group Intervention to Prevent Perinatal Depression in Youths via Interactive Maternal Group for Information and Emotional Support (IMAGINE): Pilot Cohort Study.", "datePublished": "2024-02-02", "url": "https://questionsmedicales.fr/article/38306159", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/51066" } }, { "@type": "ScholarlyArticle", "name": "Women's suggestions on how to improve the quality of maternal and newborn care: A qualitative analysis from the IMAgiNE EURO survey in Italy during the two years of the COVID-19 pandemic.", "datePublished": "2024-10-22", "url": "https://questionsmedicales.fr/article/39439544", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18332/ejm/192143" } }, { "@type": "ScholarlyArticle", "name": "Gestational diabetes mellitus care re-imagined - A cost-minimisation analysis: Cost savings from a tertiary hospital, using a novel, digital-based gestational diabetes management model.", "datePublished": "2023-05-05", "url": "https://questionsmedicales.fr/article/37144760", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ajo.13695" } }, { "@type": "ScholarlyArticle", "name": "Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study.", "datePublished": "2022-10-11", "url": "https://questionsmedicales.fr/article/36220884", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41433-022-02265-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Toxines biologiques", "item": "https://questionsmedicales.fr/mesh/D014118" }, { "@type": "ListItem", "position": 4, "name": "Facteurs de virulence", "item": "https://questionsmedicales.fr/mesh/D037521" }, { "@type": "ListItem", "position": 5, "name": "Effecteurs de type activateur de transcription", "item": "https://questionsmedicales.fr/mesh/D000071336" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Effecteurs de type activateur de transcription - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Effecteurs de type activateur de transcription", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Effecteurs de type activateur de transcription", "description": "Comment identifier les effecteurs TAL dans un échantillon ?\nQuels tests sont utilisés pour détecter les TAL ?\nLes TAL peuvent-ils être détectés par imagerie ?\nQuels marqueurs sont associés aux TAL ?\nPeut-on utiliser des anticorps pour détecter les TAL ?", "url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Imagination&page=58#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Effecteurs de type activateur de transcription", "description": "Quels sont les effets des TAL sur les cellules ?\nLes TAL provoquent-ils des symptômes cliniques ?\nComment les TAL affectent-ils les plantes ?\nLes TAL sont-ils liés à des maladies ?\nLes TAL affectent-ils le métabolisme cellulaire ?", "url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Imagination&page=58#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Effecteurs de type activateur de transcription", "description": "Comment prévenir les effets indésirables des TAL ?\nLes TAL peuvent-ils être utilisés de manière préventive ?\nQuelles mesures de sécurité sont nécessaires lors de l'utilisation des TAL ?\nLes TAL nécessitent-ils une réglementation spécifique ?\nComment évaluer l'impact environnemental des TAL ?", "url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Imagination&page=58#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Effecteurs de type activateur de transcription", "description": "Les TAL sont-ils utilisés en thérapie génique ?\nComment les TAL sont-ils appliqués en biotechnologie ?\nLes TAL peuvent-ils être utilisés pour traiter des cancers ?\nQuels sont les avantages des TAL en médecine ?\nLes TAL sont-ils sûrs pour l'utilisation humaine ?", "url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Imagination&page=58#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Effecteurs de type activateur de transcription", "description": "Quelles complications peuvent survenir avec l'utilisation des TAL ?\nLes TAL peuvent-ils provoquer des réactions immunitaires ?\nComment gérer les complications liées aux TAL ?\nLes TAL peuvent-ils affecter la biodiversité ?\nQuelles sont les préoccupations éthiques liées aux TAL ?", "url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Imagination&page=58#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Effecteurs de type activateur de transcription", "description": "Quels facteurs augmentent les risques liés aux TAL ?\nLes TAL sont-ils plus risqués dans certaines applications ?\nComment évaluer les risques des TAL en recherche ?\nLes TAL sont-ils associés à des risques environnementaux ?\nQuels sont les risques pour la santé liés aux TAL ?", "url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Imagination&page=58#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les effecteurs TAL dans un échantillon ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par PCR, séquençage ou techniques de biologie moléculaire." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les TAL ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de PCR en temps réel et des analyses de séquençage sont couramment utilisés." } }, { "@type": "Question", "name": "Les TAL peuvent-ils être détectés par imagerie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, les TAL sont des protéines et nécessitent des méthodes moléculaires pour leur détection." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux TAL ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs génétiques spécifiques aux TAL peuvent être utilisés pour leur identification." } }, { "@type": "Question", "name": "Peut-on utiliser des anticorps pour détecter les TAL ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anticorps spécifiques peuvent être utilisés dans des tests immunologiques." } }, { "@type": "Question", "name": "Quels sont les effets des TAL sur les cellules ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les TAL modifient l'expression génique, influençant la croissance et la différenciation cellulaire." } }, { "@type": "Question", "name": "Les TAL provoquent-ils des symptômes cliniques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les TAL eux-mêmes ne provoquent pas de symptômes, mais leurs effets peuvent influencer la santé cellulaire." } }, { "@type": "Question", "name": "Comment les TAL affectent-ils les plantes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent induire des réponses de défense ou des modifications de croissance chez les plantes." } }, { "@type": "Question", "name": "Les TAL sont-ils liés à des maladies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être impliqués dans des maladies en modifiant l'expression de gènes associés." } }, { "@type": "Question", "name": "Les TAL affectent-ils le métabolisme cellulaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en régulant des gènes clés, les TAL peuvent influencer le métabolisme cellulaire." } }, { "@type": "Question", "name": "Comment prévenir les effets indésirables des TAL ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une évaluation rigoureuse des TAL avant leur utilisation est essentielle pour prévenir les effets indésirables." } }, { "@type": "Question", "name": "Les TAL peuvent-ils être utilisés de manière préventive ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être utilisés pour renforcer la résistance des plantes aux maladies, par exemple." } }, { "@type": "Question", "name": "Quelles mesures de sécurité sont nécessaires lors de l'utilisation des TAL ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des protocoles de sécurité en laboratoire et des évaluations de risque sont nécessaires." } }, { "@type": "Question", "name": "Les TAL nécessitent-ils une réglementation spécifique ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, leur utilisation en biotechnologie et en médecine est soumise à des réglementations strictes." } }, { "@type": "Question", "name": "Comment évaluer l'impact environnemental des TAL ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des études d'impact environnemental doivent être réalisées avant leur déploiement dans la nature." } }, { "@type": "Question", "name": "Les TAL sont-ils utilisés en thérapie génique ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les TAL sont utilisés pour cibler et modifier des gènes dans des thérapies géniques." } }, { "@type": "Question", "name": "Comment les TAL sont-ils appliqués en biotechnologie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont utilisés pour créer des plantes génétiquement modifiées et pour la recherche génétique." } }, { "@type": "Question", "name": "Les TAL peuvent-ils être utilisés pour traiter des cancers ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des études explorent leur utilisation pour cibler des gènes spécifiques dans les cellules cancéreuses." } }, { "@type": "Question", "name": "Quels sont les avantages des TAL en médecine ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils permettent une modification précise de l'ADN, offrant des possibilités de traitement ciblé." } }, { "@type": "Question", "name": "Les TAL sont-ils sûrs pour l'utilisation humaine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des études sont en cours pour évaluer leur sécurité et leur efficacité dans des applications cliniques." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'utilisation des TAL ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des effets hors cible sur d'autres gènes peuvent survenir, entraînant des complications." } }, { "@type": "Question", "name": "Les TAL peuvent-ils provoquer des réactions immunitaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réactions immunitaires peuvent se produire si le système immunitaire reconnaît les TAL comme étrangers." } }, { "@type": "Question", "name": "Comment gérer les complications liées aux TAL ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance étroite et des ajustements dans les protocoles d'utilisation peuvent aider." } }, { "@type": "Question", "name": "Les TAL peuvent-ils affecter la biodiversité ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, leur utilisation peut avoir des impacts sur la biodiversité, nécessitant une évaluation." } }, { "@type": "Question", "name": "Quelles sont les préoccupations éthiques liées aux TAL ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les préoccupations incluent les effets sur l'environnement et la modification génétique des organismes." } }, { "@type": "Question", "name": "Quels facteurs augmentent les risques liés aux TAL ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation inappropriée ou non réglementée des TAL peut augmenter les risques associés." } }, { "@type": "Question", "name": "Les TAL sont-ils plus risqués dans certaines applications ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, leur utilisation dans des organismes vivants peut présenter des risques plus élevés." } }, { "@type": "Question", "name": "Comment évaluer les risques des TAL en recherche ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des études de sécurité et des évaluations de risque doivent être menées avant l'utilisation." } }, { "@type": "Question", "name": "Les TAL sont-ils associés à des risques environnementaux ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, leur introduction dans l'environnement peut avoir des conséquences imprévues." } }, { "@type": "Question", "name": "Quels sont les risques pour la santé liés aux TAL ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des risques pour la santé peuvent survenir si les TAL provoquent des effets indésirables non prévus." } } ] } ] }

Sources (578 au total)

A 68-Year-Old Woman Presenting with Recurrent Abdominal Pain and a Diagnosis of a Presacral Retroperitoneal Benign Schwannoma that Mimicked an Ovarian Tumor on Pelvic Magnetic Resonance Imagining.

BACKGROUND Schwannomas are benign tumors and their appearance in the pelvic region is rare and poses a major diagnostic problem. They can be sporadic or associated with genetical syndromes. They have ...

Acceptability and Utility of a Digital Group Intervention to Prevent Perinatal Depression in Youths via Interactive Maternal Group for Information and Emotional Support (IMAGINE): Pilot Cohort Study.

Perinatal depression (depression during pregnancy or the first year postpartum) affects 10%-25% of perinatal individuals, with a higher risk among youths aged <25 years. The Mothers and Babies Course ... We developed a digital adaptation of MB (Interactive Maternal Group for Information and Emotional Support [IMAGINE]) and evaluated it in a pre-post mixed methods pilot among young perinatal people in ... IMAGINE was a structured digital group of up to 7 participants, with scheduled MB content and open discussion for 12 weeks, facilitated by a social worker. Scheduled content included asynchronous SMS ... Among 68 individuals who contacted this study, 22 were screened, 13 were eligible, and 10 enrolled, for an uptake of 76.9%. Furthermore, 4 (40%) participants were pregnant at enrollment. Participants ... This pilot study provides promising evidence of the acceptability and utility of IMAGINE among perinatal youths. Our study's small sample size did not detect changes in clinical outcomes; our findings...

Women's suggestions on how to improve the quality of maternal and newborn care: A qualitative analysis from the IMAgiNE EURO survey in Italy during the two years of the COVID-19 pandemic.

Collecting women's views and suggestions for improving quality of maternal-newborn care (QMNC) is a crucial aspect of maternity care evaluation often overlooked in Italy and globally. Childbearing wom... Data were collected from an open-ended question included in a validated online questionnaire administered to mothers who gave birth in an Italian hospital between November 2020 to March 2022. The resp... The thematic analysis identified five main themes from the 2017 responses: 1) Support for mothers during the postnatal period; 2) Better use of resources; 3) Improvement of the maternity environment; ... This is the first qualitative study in Italy focusing on women's suggestions for improving QMNC during the COVID-19 pandemic. Its findings can be used to inform what aspects of QMNC need improvement i...

Gestational diabetes mellitus care re-imagined - A cost-minimisation analysis: Cost savings from a tertiary hospital, using a novel, digital-based gestational diabetes management model.

Diagnosis of gestational diabetes mellitus (GDM) in a pregnancy has a significant impact on health service resources and represents a substantial financial and time impost on women.... To describe a cost-minimisation analysis conducted following the demonstration of clinically equivalent care of women using a novel, digital model for GDM management, compared with conventional care.... A pre-implementation model of care was compared with the post-implementation model of care which included systematic development and delivery of education videos, use of the Commonwealth Scientific an... Health service costs showed a modest saving of AU$17 441.78 (US$12 158.92) in the intervention group over a 12-month period. Cost savings for the woman were estimated at $566.56 (US$394.96) per patien... Re-imagining GDM patient care by introducing a novel, digital-based GDM model of care has substantial positive cost implications for patients....

Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study.

Retinal vein occlusion (RVO) is the second most common retinal vascular disorder. Despite promising advances with anti-VEGF therapy, select patients are unresponsive to therapy. A precision medicine-b... The IMAGINE study is a post-hoc assessment of aqueous humour cytokines with correlation to higher level analysis of imaging studies. OCT scans underwent machine learning enhanced segmentation of the i... Twenty-six eyes were included. The OCT-based response schema identified 21 Responders (81%) and 5 Non-Responders (19%). VEGF levels directly correlated with intraretinal fluid volume and angiogenin wa... Cytokine expression was linked to specific OCT features and treatment response in RVO. Identification of an imaging phenotype that could serve as a surrogate for underlying active disease pathways cou...

Women 's perception on the quality of maternal and newborn care during the COVID-19 pandemic in German-speaking countries: Findings from the IMAgiNE EURO project comparing data from Germany, Switzerland and Austria.

Restrictions during the COVID-19 pandemic compromised maternal and newborn care.... Countries in the German speaking area share several clinical care guidelines but differed significantly in the strictness of COVID-19 protective measures.... To investigate the quality of maternal and newborn care (QMNC) during the COVID-19 pandemic in the German-speaking area and explore associations between the reorganisational changes due to COVID-19 an... As part of the IMAgiNE EURO study (ClinicalTrials.gov: NCT04847336), we conducted an online survey on the QMNC in the German-speaking area, including women who gave birth in Germany, Switzerland, and ... Out of a total of 70,721 women accessing the online questionnaire, 1,875 were included (Germany: n = 1,053, Switzerland: n = 494, Austria: n = 328). Significant differences across countries were found... Midwives and other health professional should pay particular attention to the provision of respectful, high-quality care.... To effectively improve QMNC, further research is essential to monitor the quality of care and develop targeted interventions beyond the COVID-19 pandemic addressing inherent challenges in the organisa...

Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial.

To investigate whether a 2-year MRI treat-to-target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-to-target strategy targeting clinica... IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly. Prespec... In total 131 patients, 86 women (67%), mean age 61.2, disease duration 9.5 years, median baseline DAS28-CRP 1.9 (IQR 1.6-2.2) and vdHSS 16.0 (IQR 7.0-36.0) were included in the study; 59 (59%) patient... A 2-year combined MRI and clinical treat-to-target strategy, compared with a conventional clinical treat-to-target strategy alone, had no effect on the long-term probability of achieving DAS28-CRP rem...

Health workers' perspectives on the quality of maternal and newborn health care around the time of childbirth: Results of the Improving MAternal Newborn carE in the EURO Region (IMAgiNE EURO) project in 12 countries of the World Health Organization European Region.

Health workers' (HWs') perspectives on the quality of maternal and newborn care (QMNC) are not routinely collected. In this cross-sectional study, we aimed to document HWs' perspectives on QMNC around... HWs involved in maternal/neonatal care for at least one year between March 2020 and March 2023 answered an online validated WHO standards-based questionnaire collecting 40 quality measures for improvi... Data from 4143 respondents were analysed. For 39 out of 40 quality measures, at least 20% of HWs reported a 'need for improvement', with large variations across countries. Effective training on health... HWs from 12 European countries reported significant gaps in QMNC, lacking association with COVID-19 pandemic trends. Routine monitoring of QMNC and tailored actions are needed to improve health servic... ClinicalTrials.gov NCT04847336....